Progyny, Inc. $PGNY Shares Sold by Versor Investments LP

Versor Investments LP reduced its stake in Progyny, Inc. (NASDAQ:PGNY) by 43.5% during the 2nd quarter, Holdings Channel reports. The fund owned 26,591 shares of the company’s stock after selling 20,507 shares during the quarter. Versor Investments LP’s holdings in Progyny were worth $585,000 as of its most recent SEC filing.

A number of other hedge funds also recently bought and sold shares of PGNY. Wealth Enhancement Advisory Services LLC acquired a new stake in shares of Progyny in the 1st quarter valued at $354,000. Nordea Investment Management AB raised its stake in Progyny by 0.6% in the second quarter. Nordea Investment Management AB now owns 183,362 shares of the company’s stock valued at $4,052,000 after buying an additional 1,140 shares in the last quarter. Voya Investment Management LLC raised its stake in Progyny by 258.2% in the first quarter. Voya Investment Management LLC now owns 185,495 shares of the company’s stock valued at $4,144,000 after buying an additional 133,703 shares in the last quarter. Millennium Management LLC raised its stake in Progyny by 7.5% in the first quarter. Millennium Management LLC now owns 1,302,890 shares of the company’s stock valued at $29,107,000 after buying an additional 90,367 shares in the last quarter. Finally, Acadian Asset Management LLC raised its stake in Progyny by 243.6% in the first quarter. Acadian Asset Management LLC now owns 205,650 shares of the company’s stock valued at $4,589,000 after buying an additional 145,802 shares in the last quarter. Institutional investors and hedge funds own 94.93% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on PGNY. Truist Financial raised their target price on Progyny from $24.00 to $27.00 and gave the stock a “hold” rating in a research report on Thursday, July 17th. Weiss Ratings reissued a “hold (c-)” rating on shares of Progyny in a report on Wednesday, October 8th. Cantor Fitzgerald reissued an “overweight” rating and set a $28.00 price objective (up previously from $26.00) on shares of Progyny in a report on Friday, August 8th. Raymond James Financial set a $28.00 price objective on shares of Progyny in a report on Friday, August 8th. Finally, Canaccord Genuity Group lifted their price target on shares of Progyny from $21.00 to $23.00 and gave the stock a “hold” rating in a research note on Wednesday, August 20th. One investment analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and four have issued a Hold rating to the company’s stock. According to data from MarketBeat, Progyny currently has an average rating of “Moderate Buy” and a consensus price target of $25.44.

Progyny Stock Up 0.8%

PGNY opened at $18.57 on Wednesday. The firm has a market cap of $1.60 billion, a price-to-earnings ratio of 31.47, a price-to-earnings-growth ratio of 1.57 and a beta of 1.29. Progyny, Inc. has a 52 week low of $13.39 and a 52 week high of $26.76. The business’s 50 day moving average is $21.13 and its two-hundred day moving average is $21.89.

Progyny (NASDAQ:PGNY) last announced its earnings results on Thursday, August 7th. The company reported $0.19 EPS for the quarter, missing analysts’ consensus estimates of $0.42 by ($0.23). The business had revenue of $332.87 million during the quarter, compared to analyst estimates of $315.70 million. Progyny had a net margin of 4.28% and a return on equity of 10.69%. The business’s revenue was up 9.5% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.17 earnings per share. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. Equities analysts expect that Progyny, Inc. will post 0.6 EPS for the current fiscal year.

Insiders Place Their Bets

In other Progyny news, EVP Allison Swartz sold 2,398 shares of Progyny stock in a transaction on Thursday, August 28th. The shares were sold at an average price of $22.96, for a total value of $55,058.08. Following the transaction, the executive vice president directly owned 79,697 shares in the company, valued at approximately $1,829,843.12. The trade was a 2.92% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Kevin K. Gordon sold 2,500 shares of Progyny stock in a transaction on Monday, August 11th. The shares were sold at an average price of $22.04, for a total transaction of $55,100.00. Following the completion of the transaction, the director owned 12,501 shares in the company, valued at approximately $275,522.04. This represents a 16.67% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 7,895 shares of company stock worth $179,311. 9.40% of the stock is currently owned by company insiders.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.